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Self-replicating RNAs, known as replicons, are model systems 
used to genetically probe numerous aspects of RNA virus life 
cycles without producing infectious virus (1–7). Replicons for 
positive-stranded RNA viruses are typically constructed using 
reverse genetics approaches to replace one or more viral 
structural proteins with selectable and reporter genes. When 
translated inside cells, replicon RNA produces viral gene 
products that establish RNA replication factories, with 
reporter genes providing readouts for replicon activity and 
selectable genes permitting selection of cells that stably 
harbor the replicon. Because key structural components of 
the virion are missing, replication proceeds without 
producing infectious virus. Replicon systems that do not 
require high containment laboratory settings have been 
invaluable as molecular virology and high-throughput drug 
development platforms, as perhaps best exemplified for 
hepatitis C virus (8, 9). 
Reverse genetics systems for SARS-CoV-2, the causative 
agent of COVID-19, have been developed for fully-infectious re-
combinant virus production (10–13) and as replicon platforms 
(14–19). In the latter case, trans-complementation of the de-
leted structural gene nucleocapsid (N) (18) or envelope (E) and 
Orf3a genes (19) can enable single-cycle infectious SARS-CoV-
2 virion production that may reduce the need for high contain-
ment for a range of applications. While these systems permit 
spike-dependent replicon delivery, interrogating newly emerg-
ing spike variants requires replicon reengineering for each var-
iant. In contrast, SARS-CoV-2 spike-pseudotyped lentiviruses 
(20–22) or chimeric rhabdoviruses (22, 23) bearing spike(s) of-
fer a rapid, plasmid-based means of virion production for spike 
directed studies (24), such as the characterization of neutraliz-
ing antibodies. There remains a need for experimental systems 
that harness the non-infectious advantages of replicons, while 
also enabling studies of virus entry and replication. In princi-
ple, combining a spike-deleted SARS-CoV-2 replicon with viral 
glycoprotein trans-complementation would achieve this goal. 
Such a system would enable isogenic studies of spike variants 
in a SARS-CoV-2 based platform, while also serving as an ap-
propriately safe-guarded infection-based means of replicon 
launch that may be extended to additional cell types by using 
heterologous viral glycoproteins. Here we describe the con-
struction, activity and single-cycle virion generation of spike-
deleted SARS-CoV-2 replicons using viral glycoprotein trans-
complementation to create replicon delivery particles (RDPs). 
 
Spike-deleted replicon design and optimization of RNA 
production 
The SARS-CoV-2 genome is thought to encode 16 non- 
structural proteins (Nsp1-Nsp16) in two overlapping reading 
frames (Orf1a/1b), as well as four structural proteins—spike (S), 
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membrane (M), envelope (E), nucleocapsid (N)—and at least 
seven accessory proteins (3a, 3c, 6, 7a, 7b, 8, and 9b) expressed 
from subgenomic RNAs or alternative reading frames (Fig. 
1A) (25, 26). We adopted a modular design to assemble a re-
plicon consisting of all viral proteins with the exception of 
the primary structural glycoprotein spike (ΔS). The spike 
transcription-regulating sequence (TRS) was instead used to 
drive expression of a gene cassette consisting of neomycin-
resistance (NeoR) and a reporter gene (nuclear-localized 
monomeric NeonGreen or secreted Gaussia luciferase) sepa-
rated by a T2A ribosome shift sequence (Fig. 1A). The plasmid 
encoding the replicon cDNA contains an upstream T7 pro-
moter at the 5′ end for in vitro transcription and a self-cleav-
ing hepatitis delta virus (HDV) ribozyme at the 3′ end, which 
cleaves after an encoded polyA sequence yielding an authen-
tic terminus. 
For replicon assembly, we employed a recently published 
RNA virus reverse genetics system in the yeast Saccharomyces 
cerevisiae (10). This system leverages transformation associ-
ated recombination (TAR) to accurately assemble numerous, 
large overlapping DNA fragments (27). Transformation of 
yeast with equimolar ratios of replicon cDNA fragments led 
to efficient replicon assembly as assessed by multiplex PCR 
(fig. S1A). We performed restriction enzyme digests of the re-
sulting DNA to assess plasmid integrity and observed that 
yeast-derived plasmids were contaminated with yeast ge-
nomic DNA and did not reveal the expected NdeI digest pat-
tern (Fig. 1B). In an alternative approach, we propagated 
yeast assembled plasmids in bacteria, which boosted plasmid 
purity, as demonstrated previously (10). However, the overall 
DNA yield was suboptimal in both instances and, in the case 
of bacterial propagation, often resulted in mutations in the 
coding region of the viral RNA-dependent RNA polymerase 
(RdRp). To improve plasmid purity and yield, we developed 
a method that relies on selective enzymatic digestion of con-
taminating yeast DNA followed by preferential amplification 
of the plasmid product. We first treated plasmid preparations 
with BamHI, which digests yeast genomic DNA but whose 
recognition sequence is absent in the replicon plasmid. We 
subsequently treated the DNA with Plasmid-Safe (PS) DNase 
to digest linear contaminating yeast DNA. We next turned to 
multiple displacement rolling circle amplification (RCA) us-
ing phi29 DNA polymerase (28) and random primers to am-
plify replicon plasmids from either yeast or sequence-verified 
bacterial clones. Due to its processivity (>70 kb per binding 
event), strand-displacement activity, and low error rate 
(<1E−6), phi29 polymerase can exponentially amplify long, cir-
cular DNA sequences with high fidelity under isothermal 
conditions and has been used to replicate bacterial artificial 
chromosomes, cosmids, mitochondrial DNA, and microbial 
genomes megabases in length (29–31). Indeed, amplification 
of replicon plasmids from yeast or bacteria yielded useful 
quantities of full length and intact replicon DNA (Fig. 1B) as 
verified by amplicon sequencing. We used the resulting DNA 
for T7 transcription reactions and observed apparently full-
length (~27.5 kb) replicon RNA in addition to shorter RNA 
products (Fig. 1C). To directly compare launch efficiency, 
mNeonGreen-encoding replicon RNAs were electroporated 
into BHK-21 cells together with additional in vitro tran-
scribed N mRNA, previously shown to boost launch efficiency 
(10, 15), and the percentage of cells expressing the mNeon-
Green reporter was measured at 24 h post electroporation. 
We observed fewer than 1% of replicon positive cells using 
RNA from non-phi29 amplified templates, where bacteria 
propagated plasmids yielded the highest (0.8%) mNeonGreen 
reporter signal (Fig. 1D). In contrast, PS DNase-treated and 
phi29-amplified templates yielded approximately 20% mNeon-
Green positive cells. The mNeonGreen signal was dependent 
on productive replication and transcription, as no signal was 
observed using replicon RNA harboring inactivating muta-
tions in Nsp12, the viral RdRp (32, 33) (Fig. 1E, pol(-)). In 
summary, the most efficient means of reaching high replicon 
launch efficiency was achieved by making capped RNA from 
yeast plasmids that are PS digested and phi29-amplified prior 
to transcription (Fig. 1F). 
 
Spike-deleted SARS-CoV-2 replicons are convenient 
and versatile assay platforms 
To characterize the utility of spike-deleted replicons for  
antiviral compound evaluation and screening, host factor  
validation, and viral mutant phenotype assessment, we con-
structed a replicon encoding secreted Gaussia luciferase 
(Gluc) (Fig. 1A). RNA transcripts were electroporated into 
Huh-7.5 cells and cumulative reporter activity per 24 h period 
was monitored via luciferase quantification from culture  
supernatant. We detected robust luciferase activity by 24 h 
post-electroporation which steadily decreased over time (Fig. 
2A). Luciferase activity was dependent on viral replication,  
as no signal was observed for the pol(-) replicon mutant.  
Replicon-driven luciferase expression was also sensitive to 
remdesivir, a well-characterized inhibitor of the SARS-CoV-2 
RdRp (34). As a luciferase-independent measure of replicon 
activity, we measured N subgenomic mRNA (sgmRNA) levels 
by qRT-PCR and observed RNA accumulation kinetics that 
paralleled reporter gene expression (Fig. 2B). This signal was 
distinct from co-electroporated N mRNA, needed for efficient 
replicon or virus launch from RNA (10), which was detectable 
in all measured samples as expected (fig. S1B). These results 
show that SARS-CoV-2 replicons undergo robust and quanti-
fiable RNA replication. 
One of the most fruitful applications for replicons are as 
drug screening platforms. As a proof-of-concept, we treated 
cells bearing luciferase reporter replicons with compounds 
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different stages of the viral life cycle: the SARS-CoV-2 RdRp 
inhibitor remdesivir (34), and masitinib, a proposed 3CLpro 
inhibitor (35). As a negative control, we used 27-hydroxycho-
lesterol (27-HC), which was reported to have both anti-SARS-
CoV-2 and anti-HCoV-OC43 activity by affecting viral entry, 
which we bypass by RNA transfection (36). We also tested a 
host-targeting agent (HTA), AM580, a retinoid derivative re-
ported to have broad antiviral activity by disrupting sterol 
regulatory element binding protein (SREBP) lipid signaling 
(37). For remdesivir, we observed IC50 values and low cytotox-
icity profiles similar to those previously reported for live virus 
(Fig. 2C) (34). For masitinib, we observed inhibition with sim-
ilar IC50 values to what was shown with infectious HCoV-
OC43 and SARS-CoV-2 (35). However, cellular toxicity was 
observed at high concentrations (Fig. 2D). For AM580, IC50 
values were consistent with reported results, with low cyto-
toxicity at inhibitory concentrations (Fig. 2E) (37). As ex-
pected, 27-HC showed no detectable inhibition (Fig. 2F). 
These representative results showcase the utility of SARS-
CoV-2 replicons as scalable drug discovery platforms focused 
on intracellular viral replication events. 
We next tested if replicons could be used to identify or 
validate intracellular SARS-CoV-2 host factors. Transmem-
brane protein 41B (TMEM41B) was recently reported to be a 
critical intracellular host factor for multiple coronaviruses 
(38). To test whether SARS-CoV-2 replicon activity depended 
on TMEM41B function, we electroporated wild-type and 
TMEM41B KO Huh-7.5 cells with reporter replicon RNA. Con-
sistent with results obtained with virus, TMEM41B KO re-
sulted in a 22-fold decrease in reporter activity compared to 
wild-type Huh-7.5 cells (Fig. 2G), an effect similar in magni-
tude to remdesivir treatment. In contrast, an alphavirus re-
plicon was not affected by TMEM41B ablation (Fig. 2H). 
TMEM41B reconstitution in KO cells led to an 11-fold rescue 
in replicon activity (Fig. 2I). These results demonstrate that 
SARS-CoV-2 replicons are sensitive to disruption of critical 
intracellular host factors. 
 
SARS-CoV-2 replicons reveal viral determinants of  
interferon sensitivity 
SARS-CoV-2 replicons can also be used to characterize viral 
mutants. Recent studies have highlighted the importance of 
Nsp1 as a suppressor of host translation (39–44) consistent 
with prior studies on SARS-CoV (45, 46). This Nsp1 activity 
can be ablated by two amino acid substitutions at positions 
164 and 165 (47) that are important for association with the 
40S ribosomal subunit (39, 40). Nsp1 mutant (Nsp1mut) repli-
cons might preserve translation and cell viability and hence 
prolong replicon activity or, given the proposed role of Nsp1 
in blunting the innate immune response (14, 39, 48), such 
mutations might attenuate the replicon. We generated 
Nsp1mut replicons and found that they performed similarly to 
wild-type versions in Huh-7.5 cells, could be inhibited by 
remdesivir (Fig. 3A), but exhibited less cellular toxicity (Fig. 
3B). In contrast, viability of cells harboring wild-type repli-
cons remained low even when replicons were launched in the 
presence of remdesivir (Fig. 3B). Taken together, these results 
suggest that the initial burst of SARS-CoV-2 Nsp1, expressed 
from transfected replicon RNA, is an important mediator of 
cell toxicity. 
As SARS-CoV-2 Nsp1 activity is proposed to halt produc-
tion of interferon-stimulated gene (ISG) products (39, 40), we 
hypothesized that Nsp1mut replicons would be more sensitive 
to interferon. Indeed, upon launch in Huh-7.5 cells, Nsp1 mu-
tants were hypersensitive to IFNα and IFNβ compared to 
wild-type replicons (Fig. 3, C and D) while both replicons ex-
hibited similar sensitivity to remdesivir (Fig. 3E). These re-
sults highlight the ability of Nsp1 to blunt the antiviral ISG 
response by inhibiting host translation, which contributes to 
cytotoxicity. While these features of Nsp1mut replicons may be 
advantageous for DAA and HTA screening, the lack of Nsp1 
functions may affect screening outcomes in different cell 
backgrounds, depending upon innate immune competence or 
other factors. Further, attempts to leverage the lower cytotox-
icity of Nsp1mut replicons to select for stable cell lines harbor-
ing non-cytopathic replicons, as done previously with HCoV-
229E (49), have thus far been unsuccessful in Huh-7.5 and 
BHK-21 cells. Different cell backgrounds and multiple adap-
tive mutations may be necessary to achieve this goal. 
 
SARS-CoV-2 replicons can be trans-complemented with 
spike to generate single-cycle virions 
While BHK-21 and Huh-7.5 cells are permissive for replicon 
launch via electroporation, physiologically relevant lung cell 
lines and primary cell types are more challenging to transfect. 
Such cells also have intact RNA sensing and innate immune 
functions, which BHK-21 and Huh-7.5 cells lack (50, 51). Elec-
troporation or other methods of RNA delivery also preclude 
the study of normal viral entry processes, and the large quan-
tities of transfected RNA do not mimic virus infection, where 
one or few RNA genomes initiate productive replication. As a 
more authentic route for replicon delivery, we attempted to 
package replicons as single-cycle virions that could infect 
cells in a spike-dependent manner but would not produce in-
fectious progeny capable of further spread. We refer to these 
single-cycle virions as replicon delivery particles (RDPs). We 
transfected BHK-21 cells with a spike-expressing plasmid and 
24 h later co-electroporated spike-deleted mNeonGreen repli-
con RNA and N mRNA (Fig. 4, A and B). The full-length na-
tive spike gene was human-codon optimized and designed to 
lack 5′UTR, leader, TRS, and 3′UTR viral sequences in order 
to minimize the possibility of recombination into the replicon 
(52, 53). Given that Nsp1 hindered cell survival post electro-
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trans-complemented more efficiently than wild-type repli-
cons. To test this, wild-type or Nsp1mut replicons were  
electroporated into spike-expressing cells. After 24 h, the 
putative RDPs were concentrated from the supernatant of 
producer cells by polyethylene glycol (PEG) precipitation 
and introduced to the culture medium of recipient Huh-7.5 
cells overexpressing ACE2 and TMPRSS2 (Huh-7.5 AT). We 
detected mNeonGreen-positive cells in a spike-dependent 
manner (Fig. 4, C and D, P1) with Nsp1mut RDPs yielding a  
5-fold higher proportion of positive cells. No mNeonGreen 
positive cells were detected upon further passage of the  
supernatant from RDP positive Huh-7.5 AT cells (P1) onto 
naïve Huh-7.5 AT cells (P2), (Fig. 4, C and D). This suggests 
that spike RDPs exhibit single-cycle infectivity. Consistent 
with this observation, spike expression was readily detected 
in the producer cells (P0), but absent in RDP-infected P1 
cells (fig. S2, A and B). N protein expression was observed 
in producer and P1 cells, but not in P2 cells as expected (fig. 
S2C). Further, consistent with a single-cycle infectivity, 
spike RDP infection did not yield characteristic syncytia  
indicative of spike expression, as is typically seen with live 
virus (fig. S2, D and E). We observed spike RDP titers of  
103-104 TCID50/ml in Huh-7.5 AT using unconcentrated 
stocks and up to 6.2 × 105 TCID50/ml upon concentration, 
with about 10-fold lower specific infectivity than virus (Fig. 
4, E to G). This may indicate that RDPs have reduced spike 
density compared to virus. 
 
Neutralization assays with RDPs recapitulate authen-
tic SARS-CoV-2 antibody phenotypes 
Spike RDPs could complement pseudovirus assays based on 
HIV-1 or vesicular stomatitis virus (VSV), with a SARS-CoV-
2-based, and therefore more authentic, single cycle alterna-
tive. We generated Nsp1mut Gluc RDPs trans-packaged with 
either the prototype spike (WA1/2020 isolate) or the B.1.351 
variant of concern (54). We performed neutralization assays 
with these RDPs using two well-characterized human mon-
oclonal antibodies, C135 and C144 capable of potently neu-
tralizing SARS-CoV-2 or pseudoviruses expressing the 
prototype spike (55). C144 binding and neutralization is ab-
lated by the spike E484K mutation, which was originally 
identified by antibody selection experiments using a VSV 
pseudovirus (56) and which later appeared in the B.1.351 
variant (54). RDPs harboring the prototype spike were  
neutralized with both antibodies, while only C135, but not 
C144, neutralized B.1.351 spike RDPs (Fig. 5, A and B).  
Neutralization curves and relative IC50 values were compa-
rable to those obtained with the respective SARS-CoV-2  
isolates (Fig. 5, D to F) and with previous reports using  
pseudovirus assays (55, 56) with the added advantage that 
RDP generation does not require deletions in the spike cod-
ing sequence (22). 
Spike-deleted SARS-CoV-2 replicons can incorporate 
VSV glycoprotein 
Efficient entry with spike RDPs appears to require high levels 
of ACE2 and TMPRSS2 in Huh-7.5 cells since RDP addition 
to Huh-7.5 or Vero cells not overexpressing these factors was 
unproductive. As numerous cell lines relevant for SARS-CoV-
2 studies may have insufficient ACE2 or TMPRSS2 levels un-
less engineered to support viral entry (57), we tested whether 
spike-deleted replicons could be packaged with VSV-G, anal-
ogous to one-way lentiviral transduction. In such systems, 
VSV-G pseudotyping provides an efficient means of lentiviral 
vector entry (58) and for RDPs might provide an ACE2-
independent means of replicon delivery. We transfected 
BHK-21 cells with a VSV-G expression plasmid followed by 
co-electroporation with spike-deleted mNeonGreen replicon 
RNA and N mRNA (Fig. 6A). The resulting RDPs in the su-
pernatant were concentrated and added to naïve Huh-7.5 
cells. After 24 h, we observed mNeonGreen-positive cells in a 
VSV-G dependent manner (Fig. 6, B and C, P1). Importantly, 
there was no measurable signal in a second passage (Fig. 6, B 
and C, P2) and no VSV-G carryover was detected in the P1 
cells (fig. S3, A and B), suggesting that VSV-G RDPs possess 
single-cycle infectivity. In contrast to spike RDPs, producer 
(P0) VSV-G expressing BHK-21 cells had a significantly higher 
ratio of mNeonGreen compared to control cells when the 
Nsp1mut replicon was used, suggestive of local VSV-G depend-
ent spread. P1 cells also exhibited higher mNeonGreen and N 
protein positivity using Nsp1mut RDPs compared to wild-type 
RDPs (Fig. 6, B and C, and fig. S3C). We observed VSV-G RDP 
titers between 1-8x103 TCID50/ml on Huh-7.5 cells. We then 
tested VSV-G RDP infectivity on additional cell types: African 
green monkey VeroE6 cells, human Caco2 intestinal epithe-
lial cells (59, 60) and both Calu3 and A549 human lung ade-
nocarcinoma cells (61–64). Additionally, we tested RDP 
activity in two lines of human airway cells: normal human 
bronchial/tracheal epithelial cells (NHBE) and normal hu-
man lung fibroblasts (NHLF) (Fig. 6D). All cells were suscep-
tible to infection with VSV-G RDPs and exhibited productive 
viral replication, as evident from mNeonGreen reporter ex-
pression. We pretreated NHBE, NHLF and A549 cells with 
100 nM remdesivir or 100 pM IFNα and subsequently added 
Gluc VSV-G RDPs. As shown in Fig. 6E, both treatments in-
hibited Gluc reporter activity to levels approaching baseline. 
Overall, these data demonstrate that VSV-G RDPs provide 
flexible means of replicon launch in primary cell contexts. 
To further examine whether VSV-G RDPs have single- 
cycle infectivity using a more sensitive approach, we gener-
ated Gluc expressing VSV-G RDPs and infected naïve Huh-7.5 
cells followed by Gluc measurements 24h later (P1). While the 
VSV-G RDP positive cells produced a robust Gluc signal, no 
signal was observed when the supernatant from P1 was con-
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supernatant was similarly concentrated and used as positive 
control for VSV-G RDP concentration and singe-cycle infec-
tion. 
 
VSV-G trans-complementation of a SARS-CoV-2  
replicon lacking all accessory genes 
As the RDP results presented thus far have relied on spike-
deleted replicons with or without mutations in Nsp1, we ex-
amined whether replicons harboring additional deletions 
could be packaged into RDPs. Previous work with SARS-CoV 
and SARS-CoV-2 has shown that M and E genes are required 
for virion morphogenesis and release (65, 66). On that basis, 
we tested VSV-G packaging of a replicon that lacked all ac-
cessory genes but retained genes encoding the structural M, 
E, and N proteins (ΔAcc) (fig. S4A). VSV-G dependent infec-
tivity was observed on recipient Huh-7.5 cells using both 
mNeonGreen and Gluc ∆Acc versions at levels comparable to 
the spike-deleted (∆S) replicon (fig. S4, B to D). Thus, acces-
sory genes are dispensable for replicon pseudotyping with 
VSV-G. 
We highlight several features of SARS-CoV-2 RDPs. First, 
RDPs enable a rapid and isogenic means of generating single-
cycle SARS-CoV-2 virions for spike-directed efforts, such as 
screening spike variants against neutralizing antibodies 
while eliminating the potential for spike mutations to arise, 
as is commonly encountered with cell culture passaged virus 
(67, 68) and for screening antibodies against additional struc-
tural proteins. Second, single-cycle infectivity can be achieved 
with VSV-G, which may be beneficial for studies in systems 
where ACE2 receptor overexpression is infeasible. Finally, in 
contrast to replicon launch by RNA transfection, RDPs can 
be frozen, stored, and distributed, since they require no spe-
cialized equipment to use once generated. These attributes 
could eventually enable high-throughput drug screening 
without the need for high containment. Overall, these fea-
tures highlight how SARS-CoV-2 spike-deleted replicons and 
RDPs provide a flexible and single-cycle infectious platform 
for future studies of this pandemic virus. 
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Fig. 1. SARS-CoV-2 replicon design and launch optimization. (A) Upper schematic: SARS-CoV-2 genome, 
with structural proteins in black. Lower schematic: Replicon amplicon fragments for yeast assembly. 
Fragments from (10) are shown in gray, fragments harboring mutations in Nsp1 or Nsp12 (pol-), are indicated. 
Reporter gene cassette in place of spike in purple; re-engineered flanking regions in blue. L: leader, UTR: 
untranslated region, pA: polyA, HDV: hepatitis delta virus, NLS: nuclear localization sequence. (B) Agarose  
gel of replicon DNA recovered from yeast or bacteria. Phi29 amplification or plasmid-Safe (PS) DNAse 
treatment indicated. Expected NdeI digest depicted at right. (C) Agarose gel of T7 RNA transcription reactions 
from DNA plasmids shown in (B). Arrow highlights the expected size of full-length RNA. Asterisk denotes 
truncated product. (D and E) Percent of mNeonGreen replicon positive BHK-21 cells from non-amplified (D) 
or phi29-amplified (E) DNA templates measured by flow cytometry. Insets show representative mNeonGreen 
(NG) and bright-field (BF) images. N = 3, error bars = SEM. Mock = no RNA electroporation. (F) Optimized 
RNA production for SARS-CoV-2 replicons. Overlapping PCR fragments are assembled in yeast and 
propagated in bacteria or yeast, in which case they are PS DNAse treated. Subsequent phi29 amplification 

















Fig. 2. SARS-CoV-2 replicons are sensitive to antiviral compounds, host factor loss, and viral 
mutant phenotypes. (A) Gaussia luciferase (Gluc) in Huh-7.5 supernatant from cells electroporated 
with Gluc replicon RNA, seeded with 100nM remdesivir (RDV) or vehicle. Mock electroporation and 
pol(-) replicons were used as controls. Dashed line indicates the limit of detection. N = 4. (B) qRT-PCR 
measurements for subgenomic N RNA for cells in (A). Signal from mock infected cells used for 
normalization (dashed line), N = 3. (C to F) Representative experiments in Huh-7.5 cells were 
electroporated with the Gluc replicon RNA and seeded with (C) remdesivir (N = 4), (D) masitinib (N = 
4), (E) AM580 (N = 3), or (F) 27-hydroxycholesterol (27-HC) (N = 3). After 24 h, Gluc signal in the 
supernatant (black circles) and cell viability (empty circles) was measured and normalized to vehicle-
treated cells, error bars = SEM. (G) IC50 values from independent experiments using the compounds 
presented in (C) to (E). (H) Parental Huh-7.5 (WT) and clonal TMEM41B KO cells were electroporated 
as in (A). Gluc was measured 24h post-electroporation, N = 4. (I) Cells as in (H) were electroporated 
with SinRep-GFP alphavirus replicon RNA. After 24 h, GFP-positive cells were quantified by flow 
cytometry, N = 3. (J) As in (H), using cells reconstituted with TMEM41B. N = 5. Error bars = SD, *** 


















Fig. 3. Nsp1 deficient replicons are hypersensitive to interferons. (A and B) Timecourse measurements of 
Gluc in the supernatant (A) or cell viability (B) of Huh-7.5 cells electroporated with WT or Nsp1 K164A/H165A 
mutant (Nsp1mut) Gluc replicon RNA. Cells were seeded with 100nM remdesivir (RDV) or vehicle and were 
washed in PBS 24 h prior to each respective timepoint collection. Mock-electroporated cells were used as 
controls for post-electroporation cell viability. The dashed line indicates the limit of detection. N = 4, error 
bars = SD. (C to E) Huh-7.5 were electroporated with WT or Nsp1mut replicon RNA and seeded on 96-well 
plates containing indicated concentrations of (C) IFNα, (D) IFNβ, or (E) remdesivir (RDV). Gluc activity 
(closed circles) and cell viability (open circles) were measured 24 h post electroporation. N = 4, error bars = 



















Fig. 4. Trans-complementation of replicons with spike yields single-cycle SARS-CoV-2. (A) A scheme to 
trans-complement replicons with ectopically expressed spike for single-cycle virion production. BHK-21 cells 
are transfected with a spike-encoding plasmid, and 24 h later are electroporated with ΔS mNeonGreen SARS-
CoV-2 replicon RNA. Supernatant from these producer cells (P0) is collected and passed onto naïve recipient 
cells (P1) yielding reporter activity. A second round of passaging onto naïve recipient cells (P2) fails to 
propagate the replicon. (B) A spike trans-complemented replicon consists of spike-deleted replicon RNA 
alongside plasmid-driven spike expression. Nsp1 mutations relative to the WT sequence are indicated. (C) BHK-
21 producer cells (P0) alone or transfected with a spike-encoding plasmid were electroporated with WT or 
Nsp1mut replicon RNAs. The RDPs in resulting supernatants were concentrated after 24 h and passaged onto 
Huh-7.5 ACE2/TMPRSS2 (Huh-7.5 AT) cells (P1 and P2) as in (A). Immunofluorescence images at 4X 
magnification of the mNeonGreen signal (green) and N antibody staining (magenta) are shown. Scale bar, 100 
μm. (D) Quantification of the percentage of NeonGreen positive cells in each passage for the results in (C). The 
dashed lines denote the lower limit of quantification. N = 8, error bars = SD. (E) TCID50/ml values of 
independently prepared SARS-CoV2 and RDP stocks were calculated by end-point dilution assay on Huh7.5 AT 
cells. Conc: stocks concentrated by PEG precipitation. n.d., not detected. (F) Genome RNA copies/ml from the 
virus and RDP stocks in (E) were calculated by qRT-PCR. (G) The ratio between RNA copies/ml in (F) and 


















Fig. 5. Neutralization assays with RDPs recapitulate authentic SARS-
CoV-2 antibody phenotypes. (A and B) Antibody neutralization assays 
in Huh-7.5 cells of Gluc RDPs trans-complemented with WA1/2020 spike 
(A) or the B.1.351 South African variant (B) in the presence of increasing 
concentrations of C144 and C135 neutralizing antibodies. Data are 
representative from two independent experiments and are normalized 
to infected cells without antibody. N = 3, error bars = SEM. IC50, 
concentration resulting in 50% reduction in relative RLU values; NA, not 
applicable. (C to E) Neutralization assays for SARS-CoV-2 RDPs or virus 
in the presence of increasing concentrations of antibody. WT spike with 
C144 antibody (C), B.1.351 spike with C144 antibody (D) and B.1.351 with 
C135 antibody (E) are shown, representative from two independent 
experiments. Data are normalized to infected cells without antibody. N = 
3, error bars = SEM. IC50, concentration resulting in 50% relative 
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Fig. 6. VSV-G pseudotyping for efficient SARS-CoV-2 replicon delivery.  
(A) Schematic of the elements required for production of VSV-G RDPs. (B) BHK-
21 producer cells (P0) alone or transfected with VSV-G were electroporated with 
WT or Nsp1mut replicons. After 48 h, RDPs in supernatants were serially passaged 
onto Huh-7.5 cells (P1 and P2). mNeonGreen signal and N antibody staining 
depicted at 4X magnification. (C) Percentage of mNeonGreen positive cells in 
each passage from (B), N = 8, error bars = SD. (D) Indicated cell lines were 
incubated with mNeonGreen VSV-G RDPs for 24 h. Brightfield and fluorescent 
images were taken at 10X magnification. Scale bars, 100 μm. (E) NHBE, NHLF 
and A549 cells were pretreated for 24 h with 100nM of remdesivir (RDV) or 
100pM of IFNα, and infected with Gluc VSV-G RDPs. Gluc activity was measured 
24 h post-infection. N = 3, error bars = SD, dashed lines: signal from mock 
infected cells. (F) Single-cycle infectivity of VSV-G RDPs. Supernatant from RDP 
infected cells (P1) was read for Gluc activity and passaged onto naive cells (P2) 
after PEG concentration. Input supernatant serves as a positive control for 
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